eFFECTOR Therapeutics Completes $45M Series A Financing

eFFECTOR Therapeutics, a San Diego, CA-based newly formed biopharmaceutical company, completed a $45m Series A financing.

Backers included U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

The company intends to use the funds to support multiple discovery programs and enable acquisition of tumor response data in patients for a lead drug candidate.

Co-founded by Kevan Shokat, Ph.D., Chair of the Department of Cellular and Molecular Pharmacology at UC San Francisco (UCSF) eFFECTOR, Davide Ruggero, Ph.D., holder of the Helen Diller Family Endowed Chair in Basic Research at UCSF, as well as other management team members, including Steve Worland, Ph.D., President and CEO, Siegfried Reich, Ph.D., Senior Vice President of Drug Discovery, Kevin Eastwood, Senior Vice President of Business Development, and James Appleman, Ph.D., a member of the Scientific Advisory Board, eFFECTOR is focused on developing small molecule drugs to selectively regulate protein synthesis, also known as translation, with an initial emphasis on cancer.
The company has an exclusive license with the University of California to technologies related to translational control.

Board members include:
– Larry Lasky, Ph.D., Partner at U.S. Venture Partners
– Ken Haas, Executive Partner at Abingworth;
– Markus Goebel, M.D., Ph.D., Managing Director at Novartis Venture Funds;
– Simeon George, M.D., Partner at SR One; and
– Carol Gallagher, Pharm.D. (Chairman of the Board).



Join the discussion